GGrantIndex
← Leaderboards

A. McGarry Houghton

Fred Hutchinson Cancer Center

Google Scholar ↗PubMed ↗ORCID ↗
$19,684,845
Attributed
$26,907,218
Total exposure
21
Grants
15
Lead (contact PI)

Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.

Funding over time

peak $5.2M · FY2006–25
$10M$7.5M$5M$2.5M$0
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25

Funding mix

By agency

NIH$41,718,799 · 22

By mechanism

P50$18,907,167 · 9
R01$12,490,630 · 6
U01$6,737,423 · 4
U24$2,860,221 · 1
K08$631,125 · 1
P30$92,233 · 1

Top collaborators

Others in their field

Top investigators on “Malignant Neoplasm Of Lung”

Research focus

Malignant Neoplasm Of LungCessation Of LifeCancer EtiologyTumorMalignant NeoplasmsLungCancer PatientSuccessNon-Small-Cell Lung CarcinomaCellsNeutrophilImmuneCohortBaseAccountingMouse ModelLung AdenocarcinomaTumor MicroenvironmentSurvival RateProgramsDesignDiagnosisImmune Checkpoint InhibitorProteins

Grant awards (85)

Fred Hutchinson Cancer Center Lung SPORE$2,471,718
P50 · FY2025 · CA · contact PI
A Quantitative PET/CT Research Resource for Co-Clinical Imaging of Lung Cancer Therapies$636,517
U24 · FY2025 · CA
Translating Autoantibodies Into Chimeric Antigen Receptor-T cell Therapy for Small Cell Lung Cancer$625,024
U01 · FY2025 · CA
Neutrophil derived proteinases abolish the IFNG signature in NSCLC$584,823
R01 · FY2025 · CA · contact PI
Administrative Core$308,965
P50 · FY2025 · CA · contact PI
Project 1: Targeting Neutrophils to Enhance ICI Efficacy in NSCLC$308,964
P50 · FY2025 · CA · contact PI
Lung Cancer$92,233
P30 · FY2025 · CA · contact PI
Translating Autoantibodies Into Chimeric Antigen Receptor-T cell Therapy for Small Cell Lung Cancer$565,815
U01 · FY2024 · CA
Neutrophil derived proteinases abolish the IFNG signature in NSCLC$555,585
R01 · FY2024 · CA · contact PI
A Quantitative PET/CT Research Resource for Co-Clinical Imaging of Lung Cancer Therapies$549,873
U24 · FY2024 · CA
Tumor-specific autoantibodies for SCLC early detection$406,116
R01 · FY2024 · CA · contact PI
Liquid biopsy of the lung to profile lung cancer$377,741
U01 · FY2024 · CA
Fred Hutchinson Cancer Research Center Lung SPORE$2,447,085
P50 · FY2023 · CA · contact PI
Neutrophil derived proteinases abolish the IFNG signature in NSCLC$573,105
R01 · FY2023 · CA · contact PI
Tumor-specific autoantibodies for SCLC early detection$431,826
R01 · FY2023 · CA · contact PI
A Quantitative PET/CT Research Resource for Co-Clinical Imaging of Lung Cancer Therapies$389,775
U24 · FY2023 · CA
Liquid biopsy of the lung to profile lung cancer$389,670
U01 · FY2023 · CA
Project 1: Targeting the Neutrophil Lineage To Enhance Immune Checkpoint Inhibitor Efficacy in NSCLC$346,435
P50 · FY2023 · CA · contact PI
Administrative Core$228,525
P50 · FY2023 · CA · contact PI
Developmental Research Program$81,843
P50 · FY2023 · CA · contact PI
Fred Hutchinson Cancer Research Center Lung SPORE$2,447,059
P50 · FY2022 · CA · contact PI
A Quantitative PET/CT Research Resource for Co-Clinical Imaging of Lung Cancer Therapies$623,787
U24 · FY2022 · CA
Mechanisms of Tumor Derived Neutrophil Induced Apoptosis in Lymphocytes$447,953
R01 · FY2022 · CA · contact PI
Liquid biopsy of the lung to profile lung cancer$389,670
U01 · FY2022 · CA
Project 1: Targeting the Neutrophil Lineage To Enhance Immune Checkpoint Inhibitor Efficacy in NSCLC$346,435
P50 · FY2022 · CA · contact PI
Tumor-specific autoantibodies for SCLC early detection$273,780
R01 · FY2022 · CA · contact PI
Administrative Core$228,525
P50 · FY2022 · CA · contact PI
Tumor-specific autoantibodies for SCLC early detection$148,883
R01 · FY2022 · CA · contact PI
Mechanisms of Tumor Derived Neutrophil Induced Apoptosis in Lymphocytes$88,718
R01 · FY2022 · CA · contact PI
Developmental Research Program$81,843
P50 · FY2022 · CA · contact PI
Fred Hutchinson Cancer Research Center Lung SPORE$1,863,485
P50 · FY2021 · CA · contact PI
A Quantitative PET/CT Research Resource for Co-Clinical Imaging of Lung Cancer Therapies$660,269
U24 · FY2021 · CA
Fred Hutchinson Cancer Research Center Lung SPORE$581,779
P50 · FY2021 · CA · contact PI
Tumor-specific autoantibodies for SCLC early detection$432,640
R01 · FY2021 · CA · contact PI
Project 1: Targeting the Neutrophil Lineage To Enhance Immune Checkpoint Inhibitor Efficacy in NSCLC$263,281
P50 · FY2021 · CA · contact PI
Liquid biopsy of the lung to profile lung cancer$259,026
U01 · FY2021 · CA
Mechanisms of Tumor Derived Neutrophil Induced Apoptosis in Lymphocytes$256,852
R01 · FY2021 · CA · contact PI
Mechanisms of Tumor Derived Neutrophil Induced Apoptosis in Lymphocytes$218,585
R01 · FY2021 · CA · contact PI
Administrative Core$173,930
P50 · FY2021 · CA · contact PI
Liquid biopsy of the lung to profile lung cancer$143,097
U01 · FY2021 · CA
Project 1: Targeting the Neutrophil Lineage To Enhance Immune Checkpoint Inhibitor Efficacy in NSCLC$82,973
P50 · FY2021 · CA · contact PI
Mechanisms of Tumor Derived Neutrophil Induced Apoptosis in Lymphocytes$72,186
R01 · FY2021 · CA · contact PI
Developmental Research Program$62,196
P50 · FY2021 · CA · contact PI
Administrative Core$54,479
P50 · FY2021 · CA · contact PI
Anxa2 drives the function of immune suppressive neutrophils in lung cancer$40,193
R01 · FY2021 · CA · contact PI
Developmental Research Program$19,602
P50 · FY2021 · CA · contact PI
Fred Hutchinson Cancer Research Center Lung SPORE$2,509,264
P50 · FY2020 · CA · contact PI
Tumor-specific autoantibodies for SCLC early detection$573,272
R01 · FY2020 · CA · contact PI
Mechanisms of Tumor Derived Neutrophil Induced Apoptosis in Lymphocytes$457,095
R01 · FY2020 · CA · contact PI
Project 1: Targeting the Neutrophil Lineage To Enhance Immune Checkpoint Inhibitor Efficacy in NSCLC$450,659
P50 · FY2020 · CA · contact PI
Liquid biopsy of the lung to profile lung cancer$427,888
U01 · FY2020 · CA
Administrative Core$305,874
P50 · FY2020 · CA · contact PI
Developmental Research Program$83,600
P50 · FY2020 · CA · contact PI
Fred Hutchinson Cancer Research Center Lung SPORE$2,491,191
P50 · FY2019 · CA · contact PI
Hybrid Plasma Markers that Complement CT Imaging for Early Lung Cancer Detection$467,030
U01 · FY2019 · CA
Mechanisms of Tumor Derived Neutrophil Induced Apoptosis in Lymphocytes$443,381
R01 · FY2019 · CA · contact PI
IRS-1 Regulates Inflammatory Cell Recruitment in Lung Cancer$384,088
R01 · FY2019 · CA · contact PI
Project 1: Targeting the Neutrophil Lineage To Enhance Immune Checkpoint Inhibitor Efficacy in NSCLC$346,435
P50 · FY2019 · CA · contact PI
Administrative Core$239,182
P50 · FY2019 · CA · contact PI
Developmental Research Program$81,840
P50 · FY2019 · CA · contact PI
Using genetically engineered mouse models of brain tumors to develop therapeutic nanoparticles & biomaterials$633,241
R01 · FY2018 · CA
Mechanisms of Tumor Derived Neutrophil Induced Apoptosis in Lymphocytes$503,575
R01 · FY2018 · CA · contact PI
Hybrid Plasma Markers that Complement CT Imaging for Early Lung Cancer Detection$481,475
U01 · FY2018 · CA
IRS-1 Regulates Inflammatory Cell Recruitment in Lung Cancer$396,096
R01 · FY2018 · CA · contact PI
Using genetically engineered mouse models of brain tumors to develop therapeutic nanoparticles & biomaterials$644,838
R01 · FY2017 · CA
Hybrid Plasma Markers that Complement CT Imaging for Early Lung Cancer Detection$516,409
U01 · FY2017 · CA
IRS-1 Regulates Inflammatory Cell Recruitment in Lung Cancer$396,219
R01 · FY2017 · CA · contact PI
Using genetically engineered mouse models of brain tumors to develop therapeutic nanoparticles & biomaterials$657,360
R01 · FY2016 · CA
Hybrid Plasma Markers that Complement CT Imaging for Early Lung Cancer Detection$494,170
U01 · FY2016 · CA
"Neutrophil Elastase Links Idiopathic Pulmonary Fibrosis and Lung Cancer"$428,600
R01 · FY2016 · HL · contact PI
IRS-1 Regulates Inflammatory Cell Recruitment in Lung Cancer$396,340
R01 · FY2016 · CA · contact PI
Proteomic, Glycomic and Autoantibody Lung Cancer Biomarker Validation$372,766
U01 · FY2016 · CA
Hybrid Plasma Markers that Complement CT Imaging for Early Lung Cancer Detection$513,793
U01 · FY2015 · CA
"Neutrophil Elastase Links Idiopathic Pulmonary Fibrosis and Lung Cancer"$422,171
R01 · FY2015 · HL · contact PI
IRS-1 Regulates Inflammatory Cell Recruitment in Lung Cancer$415,457
R01 · FY2015 · CA · contact PI
Proteomic, Glycomic and Autoantibody Lung Cancer Biomarker Validation$364,038
U01 · FY2015 · CA
Proteomic, Glycomic and Autoantibody Lung Cancer Biomarker Validation$349,811
U01 · FY2014 · CA
"Neutrophil Elastase Links Idiopathic Pulmonary Fibrosis and Lung Cancer"$408,027
R01 · FY2013 · HL · contact PI
"Neutrophil Elastase Links Idiopathic Pulmonary Fibrosis and Lung Cancer"$428,600
R01 · FY2012 · HL · contact PI
"Neutrophil Elastase Links Idiopathic Pulmonary Fibrosis and Lung Cancer"$371,025
R01 · FY2011 · HL · contact PI
Interrelationships Between COPD, Inflammation, and Lung Tumorigenesis$126,225
K08 · FY2010 · HL · contact PI
Interrelationships Between COPD, Inflammation, and Lung Tumorigenesis$126,225
K08 · FY2009 · HL · contact PI
Interrelationships Between COPD, Inflammation, and Lung Tumorigenesis$126,225
K08 · FY2008 · HL · contact PI
Interrelationships Between COPD, Inflammation, and Lung Tumorigenesis$126,225
K08 · FY2007 · HL · contact PI
Interrelationships Between COPD, Inflammation, and Lung Tumorigenesis$126,225
K08 · FY2006 · HL · contact PI